Efficacy and Safety of High-Dose Rate Brachytherapy With Immunotherapy and Chemotherapy as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

NCT06518018 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Advanced Stage NSCLC
Second-line Treatment
Patients Without Targetable Driver Mutations

Interventions

RADIATION: HDR brachytherapy (30Gy single fraction)
DRUG: Immunotherapy

Sponsor

The First People's Hospital of Neijiang